During the past decade, Harmonex Neuroscience Research conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 34 clinical trials were completed, i.e. on average, 103% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 22 clinical trials were completed. i.e. 314.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Harmonex Neuroscience Research" #1 sponsor was "Shire" with 11 trials, followed by "Sunovion" with 8 trials sponsored, "Forest Laboratories" with 4 trials sponsored, "Naurex, Inc, an affiliate of Allergan plc" with 4 trials sponsored and "Hoffmann-La Roche" with 4 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Harmonex Neuroscience Research" #1 collaborator was "Otsuka America Pharmaceutical" with 2 trials as a collaborator, "Takeda Development Center Americas, Inc." with 1 trials as a collaborator and "The Emmes Company, LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Harmonex Neuroscience Research" are "Attention Deficit Hyperactivity Disorder (ADHD)" (6 trials), "Autism Spectrum Disorder" (5 trials), "Depressive Disorder, Major" (5 trials), "Major Depressive Disorder" (5 trials) and "ADHD" (3 trials). Many other conditions were trialed in "Harmonex Neuroscience Research" in a lesser frequency.

Most popular intervention types in "Harmonex Neuroscience Research" are "Drug" (47 trials), "Other" (4 trials), "Device" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "Aripiprazole" (4 trials), "Lurasidone" (4 trials), "Rapastinel" (4 trials) and "SHP465" (3 trials). Other intervention names were less common.

The vast majority of trials in "Harmonex Neuroscience Research" are 50 trials for "All" genders.

Currently, there are NaN active trials in "Harmonex Neuroscience Research". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 38 completed trials in Harmonex Neuroscience Research, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Harmonex Neuroscience Research, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".